An 82 year old woman was admitted with worsening dyspnoea. Arterial blood gases were taken on air and revealed a pH of 7.39, with a partial pressure of CO2 (pCO2) of 1.2 kPa, pO2 of 19.3 kPa, HCO3 of 13.8 mmol/litre, and base excess of −16.3 mmol/litre: a compensated metabolic acidosis with hyperventilation induced hypocapnia, which is known to be a feature of lactic acidosis. There was also an increased anion gap (Na140 + K4.0 – (Cl 106 + HCO3 13.8) = 24.2 mEq/litre (reference range, 7–16)), consistent with unmeasured cation. Lactate was measured and found to be raised at 3.33 mmol/litre (reference range, 0.9–1.7). After exclusion of common causes of lactic acidosis Atorvastatin was stopped and her acid-base balance returned to normal. Subsequently, thiamine was also shown to be deficient. The acidosis was thought to have been the result of a mitochondrial defect caused by a deficiency of two cofactors, namely: ubiquinone (as a result of inhibition by statin) and thiamine (as a result of dietary deficiency).

An 82 year old woman was admitted after six weeks of worsening dyspnoea. She was breathless at rest and unable to carry out her normal daily activities. She reported no fever, cough, chest pain, or orthopnoea. She had a history of chronic obstructive pulmonary disease, mild hypertension, and had suffered a deep vein thrombosis 12 months previously. Drug regimen on admission was Becloamethsone inhaler, 200 µg twice daily (bd); salbutamol inhaler, 200 µg four times daily (qds); salmeterol inhaler, 200 µg qds; prednisolone 5 mg once daily (od); ciprofloxacin, 500 mg bd (started two days before admission); lansoprazole, 15 mg od; fluoxetine, 20 mg od; coamilofrure, 3.9 mmol/litre. Her lactate had returned to normal pO2 of 19.3 kPa, HCO3 of 13.8 mmol/litre, and base excess of −16.3 mmol/litre: a compensated metabolic acidosis with hyperventilation induced hypocapnia, which is known to be a feature of lactic acidosis. There was also an increased anion gap ((Na140 + K4.0) – (Cl 106 + HCO3 13.8) = 24.2 mEq/litre (reference range, 7–16)), consistent with unmeasured cation (lactate). This was thought probably to be contributing to her dyspnoea and a cause was sought. She was on no medications that are known to cause a metabolic acidosis and was not known to be diabetic, with normal blood glucose readings. Her renal function was good (admission creatinine, 118 µmol/litre (reference range, 50–110)), but her estimated glomerular filtration rate was decreased at 26.6 ml/minute (calculated by Cockcroft and Gault equation) and her liver function tests showed no rises in transaminases or bilirubin. Lactate was measured and found to be raised at 3.33 mmol/litre (reference range, 0.9–1.7). The patient was not hypoxic because her ABGs on air showed acceptable pO2 and she was not clinically septic. Furthermore, she was not diabetic and was therefore not on oral hypoglycaemic agents, which have been associated with lactic acidosis (especially biguanides—phenformin—which is now withdrawn from use).1 A more obscure cause for her lactic acidosis was looked for.

Normal sodium and potassium values on admission (Na, 139 mmol/litre; K, 4.0 mmol/litre) were thought to exclude a renin–aldosterone axis cause (specifically hypoaldosteronism). Renin (4.1 mmol/litre/h (reference range, 0.76–3.2 erect)) and aldosterone (1041 pmol/litre (reference range, 110–860 erect)) were mildly raised, but these values were felt to be consistent with her diuretic treatment. Vitamin D (25-OH cholecalciferol) was normal: 24.5 µg/litre (reference range, 20–50). Baseline vitamin B12 (as a result of inhibition by atorvastatin) and folic acid (as a result of inhibition by co-amoxiclav) were normal. Liver function tests showed no rises in transaminases or bilirubin. Lactate was measured and found to be raised at 3.33 mmol/litre (reference range, 0.9–1.7). The patient was not hypoxic because her ABGs on air showed acceptable pO2 and she was not clinically septic. Furthermore, she was not diabetic and was therefore not on oral hypoglycaemic agents, which have been associated with lactic acidosis (especially biguanides—phenformin—which is now withdrawn from use).1 A more obscure cause for her lactic acidosis was looked for.

The only likely remaining causes were a metabolic myopathy and thiamine deficiency. It is well known that statins can cause myopathy and rhabdomyolysis.2 The patient was taking Atorvastatin at 10 mg/day. This was stopped and she immediately improved clinically. Her ABGs and lactate values repeated one week later revealed pH 7.44, pCO2 of 3.9 kPa, pO2 of 10.8 kPa, HCO3 of 22.3 mmol/litre, and base excess of −3.9 mmol/litre. Her lactate had returned to normal at 1.71 mmol/litre. Her dyspnoea was also moderately improved. Therefore, it was possible that the lactic acidosis was related to the statin treatment. Six weeks later, the results of red cell transketolase enzyme activity became available: transketolase 0.65 U/g haemoglobin (reference range, 0.42–1.12), with a > 50% increase in activity when thiamine was added to the assay reagent (reference, < 25%), indicating frank thiamine deficiency. She was therefore started on thiamine treatment at this time.

**Abbreviations:** ABGs, arterial blood gases; bd, twice daily; coQ10, coenzyme Q10; HMGCoA, hydroxymethylglutaryl CoA; od, once daily; qds, four times daily; P, partial pressure
DISCUSSION

We have reported an unusual case of lactic acidosis that appeared to resolve as a result of cessation of statin treatment. Possible causes for lactic acidosis included thiamine deficiency, vitamin D deficiency, myeloma, or abnormal renin–aldosterone functioning. It was later found that thiamine deficiency was also present and this may have acted in tandem with the statin to cause lactic acidosis, when neither element individually would have been sufficient.

Statins work by inhibiting hydroxymethylglutaryl-CoA (HMG-CoA) reductase, but in addition to reducing cholesterol synthesis there is a decrease in the production of other non-sterols, such as coenzyme Q₁₀ (coQ₁₀; ubiquinone), and HMGCoa reductase inhibitors have been shown to reduce coQ₁₀ concentrations. CoQ₁₀ is an essential carrier in the mitochondrial respiratory chain that participates in oxidative phosphorylation. Consequently, there is decreased activity of mitochondrial complex 1 with inadequate substrate (acyetyl-CoA and α-ketoglutarate tricarboxylic acid cycle effect) and reduced electron carrier transport (coQ₁₀ effect). One possible case has been reported, although that patient also had signs of hepatitis, which was not present in our patient.

Thus, both statin treatment, via decreased coQ₁₀, and thiamine deficiency, via reduced α-ketoglutarate dehydrogenase complex activity, can result in impairment of mitochondrial oxidative phosphorylation. It is possible that the lactic acidosis was the result of the combination of both thiamine deficiency and statin treatment, such that removal of one element was sufficient to resolve the metabolic stress and result in the resolution of acidosis.

REFERENCES